Skip to main content
Fig. 3 | BMC Endocrine Disorders

Fig. 3

From: The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas

Fig. 3

Comparison of the effects of bromocriptine on MAPK11/12/13/14 and PRL in GH3 cells and MMQ cells. a, b Western blot analysis of the protein expression of MAPK11, MAPK12, MAPK13, MAPK14 and PRL after treating GH3 cells and MMQ cells with different concentrations of bromocriptine(12.5 μM, 25 μM, 50 μM, 100 μM) for 48 h.*p < 0.05 vs. 0 μM,**p < 0.01 vs. 0 μM,***p < 0.001 vs. 0 μM,****p < 0.0001 vs. 0 μM, (n = 3). c RT-qPCR analysis of MAPK11, MAPK14 and PRL mRNA expression after bromocriptine treatment of GH3 cells and MMQ cells for 48 h.**p < 0.01 vs. 0 μM,***p < 0.001 vs. 0 μM,****p < 0.0001 vs. 0 μM, (n = 3)

Back to article page